The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
about
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trialDementiaA fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's diseaseDementia.Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly.Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study.Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severityClinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.A systematic review of assessment and treatment of moderate to severe Alzheimer's disease.Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysisSymptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials.Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy.Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanismsLanguage impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors.Memantine: efficacy and safety in mild-to-severe Alzheimer's disease.Update on the use of memantine in Alzheimer's disease.Reliability and validity of the severe impairment battery (SIB) in Korean dementia patients.Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease.Rivastigmine in moderately severe-to-severe Alzheimer's disease: Severe Impairment Battery factor analysis.Recommended measures for the assessment of cognitive and physical performance in older patients with dementia: a systematic reviewAnalyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease.Donepezil 23 mg: An empty suit.Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study.Cognitive Profiles on the Severe Impairment Battery Are Similar in Alzheimer Disease and Down Syndrome With Dementia.Brief cognitive assessment of Alzheimer's disease in advanced stages: Proposal for a Brazilian version of the Short Battery for Severe Impairment (SIB-8).
P2860
Q21144654-D0DE7363-6A05-4E86-8AEF-E734A0EDB7ECQ24555726-D6123905-7BFA-4C4C-B4B8-09468D87B2C2Q26860881-34CAD63C-A55B-44AA-A196-78D7D0604CA2Q28076715-93981814-DE5D-44F6-9137-08ACA747D3D5Q30404451-F8DBEF63-23FB-4C76-8E8A-B5FED8968256Q33208045-2B5E709A-78D3-4A90-92A7-E977E7FE8D96Q33248004-F4B53B9E-4D38-4A2A-B97E-A12EA4C5F128Q33630085-570E0470-B2B1-417E-A5F2-0ADEA8F7DC64Q33746082-3A327201-991E-47D9-99C2-68AAB654976CQ34408888-699265BE-9341-44B7-A839-5E29EE487FD2Q34746698-5CAE872F-C884-4205-A001-C5B568DF07EEQ34977044-FC993305-CEB7-4F9D-ACA8-2DFBC392FAFDQ35620305-A618D73C-9AA0-45BA-A731-7A6C80627467Q35765716-152A5214-D6B5-4008-AC25-AEE69BC0877DQ36478302-786D5DA0-C3AB-4E4D-88CF-D447C04B074EQ36632693-8EF0B1AC-0BD6-494E-8DA3-87CA20FF7147Q36712099-BFA70862-69C3-47C5-83F6-91942BB3D629Q37084847-8E56E667-32B2-4E95-84CF-D7FAD5433F46Q37125743-68326C46-6ADD-4DA1-86C1-3AFC0D0CD847Q37224558-D160A3BF-32A2-4ACA-83C9-745A0E4A9C16Q37313375-5C8746EA-9D9A-4700-A7BC-1ED05A544A56Q37411818-1D66F2E7-581A-44B9-A700-68C2FCA66627Q37690174-9DEA50E5-10B7-45BF-B1DB-562A94E68F31Q38076109-44E5D04E-A6B1-453B-89E7-EDD1AB19543EQ38489147-F4D81A0F-08BA-4390-9A5D-412172040EAAQ39473075-5B34C614-C45A-40F9-97D4-43E1A5F8965FQ41969658-3FDF6F33-78D5-495E-A18C-8F10371E2FBFQ46012909-A9A1ABD3-56A8-481A-BF27-C4B780427F2FQ47103059-51B889FC-3409-4EF8-9E79-5BB35275DDC7
P2860
The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
The severe impairment battery: ...... r's Disease Cooperative Study.
@ast
The severe impairment battery: ...... r's Disease Cooperative Study.
@en
The severe impairment battery: ...... r's Disease Cooperative Study.
@nl
type
label
The severe impairment battery: ...... r's Disease Cooperative Study.
@ast
The severe impairment battery: ...... r's Disease Cooperative Study.
@en
The severe impairment battery: ...... r's Disease Cooperative Study.
@nl
prefLabel
The severe impairment battery: ...... r's Disease Cooperative Study.
@ast
The severe impairment battery: ...... r's Disease Cooperative Study.
@en
The severe impairment battery: ...... r's Disease Cooperative Study.
@nl
P2093
P1476
The severe impairment battery: ...... er's Disease Cooperative Study
@en
P2093
F A Schmitt
J A Mackell
L S Schneider
P407
P478
11 Suppl 2
P577
1997-01-01T00:00:00Z